You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 6,039,931


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,039,931
Title: Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
Abstract:Compounds of general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue wherein m and n means the numbers 0-20, k, l, q and r means the numbers 0 and 1, and R means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning it hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group, X means a hydrogen atom and/or a metal ion equivalent of an element of atomic number 21-29, 42, 44 or 57-83, with the provisos that at least two the substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and l each mean the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.5, as well as their salts with inorganic and/or organic bases, amino acids or amino acid amides, are valuable pharmaceutical agents, e.g., for NMR.
Inventor(s): Schmitt-Willich; Heribert (Berlin, DE), Platzek; Johannes (Berlin, DE), Gries; Heinz (Berlin, DE), Schumann-Giampieri; Gabrielle (Berlin, DE), Weinmann; Hanns-Joachim (Berlin, DE), Vogler; Hubert (Berlin, DE), Deutsch; Julius (Berlin, DE), Conrad; Juergen (Berlin, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:08/319,357
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patent 6,039,931

Introduction

U.S. Patent 6,039,931, issued to Bayer Schering Pharma Aktiengesellschaft, is a significant patent in the pharmaceutical sector. To analyze its scope and claims, and to understand its place within the patent landscape, we need to delve into several key aspects.

Patent Overview

Patent Type and Issuance

U.S. Patent 6,039,931 is a utility patent, which is one of the three main types of patents issued by the United States Patent and Trademark Office (USPTO), along with design and plant patents[1].

Inventor and Assignee

The patent was assigned to Bayer Schering Pharma Aktiengesellschaft, a major pharmaceutical company. Understanding the assignee can provide insights into the commercial and strategic implications of the patent.

Claims Analysis

Claim Structure

Patent claims are the heart of any patent, defining the scope of protection granted to the inventor. The claims of U.S. Patent 6,039,931 would typically include a set of independent and dependent claims. Independent claims stand alone and define the broadest scope of the invention, while dependent claims narrow down the scope by adding additional limitations[3].

Subject Matter

The patent claims would be directed to a new and useful process, machine, manufacture, or composition of matter, or any improvement thereof, as required by 35 U.S.C. § 101[2].

Scope of the Invention

Invention Description

The patent describes a human drug product, which suggests it involves a specific formulation, method of use, or composition related to pharmaceuticals. The detailed description would include how the drug is prepared, its active ingredients, and any unique aspects that differentiate it from prior art.

Novelty and Non-Obviousness

For a patent to be granted, the invention must be novel and non-obvious over the prior art. The claims would need to demonstrate an inventive step that transforms the abstract idea or natural phenomenon into a patent-eligible invention, as per the "Alice" test[2].

Patent Landscape

Prior Art and Related Patents

To understand the patent landscape, one must conduct a thorough search of prior art and related patents. Tools such as the USPTO's Patent Public Search, Global Dossier, and databases from other international intellectual property offices can be used to identify similar patents and determine the novelty of the invention[4].

Competitors and Market Impact

Analyzing the patent landscape also involves identifying competitors who may be working on similar technologies. This can include other pharmaceutical companies that have filed or been granted patents in the same field.

Legal and Regulatory Considerations

Patent Eligibility

The patent must comply with the eligibility criteria under 35 U.S.C. § 101. The "Alice" test is a crucial framework for determining whether the claims are directed to patent-ineligible subject matter, such as abstract ideas or natural phenomena[2].

Litigation and Enforcement

Patents can be subject to litigation, especially if there are disputes over infringement or validity. The case of Broadband iTV, Inc. v. Amazon.com, Inc. illustrates how patent eligibility can be challenged in court, highlighting the importance of robust claims that withstand legal scrutiny[2].

Searching and Analyzing Patents

Tools and Resources

Several tools are available for searching and analyzing patents, including the USPTO's Patent Public Search, Global Dossier, and the Patent and Trademark Resource Centers (PTRCs). These resources help in identifying prior art, understanding the patent family, and analyzing the scope of the patent claims[4].

International Considerations

Given the global nature of pharmaceutical research, it is essential to search international patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO)[4].

Economic and Strategic Implications

Market Dominance

A strong patent like U.S. Patent 6,039,931 can provide significant market dominance by preventing others from making, using, or selling the invention in the United States for a limited time period[1].

Licensing and Collaboration

Patents can also be used as a tool for licensing and collaboration. Companies may license their patents to other entities, generating revenue and fostering innovation.

Key Takeaways

  • Patent Claims: The claims define the scope of protection and must be novel and non-obvious.
  • Patent Landscape: Understanding related patents and prior art is crucial for determining the novelty and market impact.
  • Legal Considerations: Compliance with patent eligibility criteria and potential litigation risks are important.
  • Tools and Resources: Utilizing USPTO and international databases is essential for thorough patent analysis.
  • Economic Implications: Strong patents can lead to market dominance and revenue through licensing.

FAQs

Q: What is the primary purpose of patent claims in a utility patent? A: The primary purpose of patent claims is to define the scope of protection granted to the inventor, distinguishing the invention from prior art.

Q: How can one determine if a patent claim is eligible under 35 U.S.C. § 101? A: The "Alice" test is used to determine patent eligibility, involving a two-step process to check if the claim is directed to an abstract idea and if it includes elements that transform it into a patent-eligible application.

Q: What resources are available for searching and analyzing U.S. patents? A: Resources include the USPTO's Patent Public Search, Global Dossier, Patent and Trademark Resource Centers (PTRCs), and international patent databases like those from the EPO and WIPO.

Q: Can a patent be used to prevent others from importing the invention into the United States? A: Yes, a U.S. patent grants the exclusive right to prevent others from importing the invention into the United States[1].

Q: How long does a U.S. patent provide exclusive rights? A: A U.S. patent typically provides exclusive rights for a limited time period, usually 20 years from the date of filing the patent application[1].

Sources

  1. United States Patents: Collections - NYS Library
  2. BROADBAND ITV, INC. v. AMAZON.COM, INC.
  3. Patent Claims Research Dataset - USPTO
  4. Search for patents - USPTO

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,039,931

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,039,931

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany39 22 005Jun 30, 1989

International Family Members for US Patent 6,039,931

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 0405704 ⤷  Subscribe 300182 Netherlands ⤷  Subscribe
European Patent Office 0405704 ⤷  Subscribe SPC/GB05/021 United Kingdom ⤷  Subscribe
European Patent Office 0405704 ⤷  Subscribe C00405704/01 Switzerland ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.